DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DEXCOM INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$85.98−0.06 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $33.54B
- P/E (TTM)
- 34.1
- Dividend yield
- –
DEXCOM INC revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.51B | $3.42B | $3.33B | $3.25B | $3.10B | $2.99B | $2.89B | $2.86B | $2.87B | $2.75B | $2.63B | $2.46B | 70.6% | +13.3% |
| International | $1.46B | $1.40B | $1.33B | $1.27B | $1.20B | $1.16B | $1.14B | $1.10B | $1.07B | $1.05B | $997.00M | $940.40M | 29.4% | +21.2% |
From the segment and revenue-disaggregation notes of Dexcom's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.